Herd immunity (or community immunity) occurs when a large proportion of a community is immune to a disease, making the spread of the disease from person to person unlikely. This high level of immunity provides indirect protection to individuals who are not immune, such as infants too young to be vaccinated, or those with contraindications. At 9 months, maternal IgG antibodies have waned significantly and would not provide reliable protection.

The clinical manifestations of tetanus are caused by a potent neurotoxin (tetanospasmin) produced by Clostridium tetani, not by the bacterium itself. The tetanus vaccine contains a toxoid, which is an inactivated form of the toxin. The vaccine induces the production of neutralizing antibodies that bind to the circulating neurotoxin and prevent it from reaching its target in the central nervous system, thereby preventing the symptoms of tetanus.

The anamnestic, or secondary, immune response is mediated by pre-existing memory lymphocytes. It is qualitatively and quantitatively different from a primary response. Key features include a shorter lag phase (faster response), a much higher peak level of antibody production, and a predominance of high-affinity IgG antibodies due to isotype switching and affinity maturation that occurred during the primary response. It relies on the activation of memory cells, not naive lymphocytes.

Live attenuated vaccines contain weakened but viable pathogens. In immunocompetent individuals, the immune system, particularly cell-mediated immunity driven by T-cells, can easily control the replication of the attenuated organism. In a patient with SCID who lacks functional T-cells, the attenuated virus can replicate uncontrollably, leading to a severe, disseminated, and potentially fatal infection. While failure to produce antibodies is also expected, the immediate life-threatening risk is uncontrolled viral replication.

mRNA vaccines work by delivering an mRNA template to the host's own cells. The lipid nanoparticle facilitates entry into the cytoplasm, where the mRNA is translated by the host cell's ribosomes into the viral spike protein. This newly synthesized protein is then processed and presented by the host cell on both MHC class I and II molecules (after secretion and uptake by APCs), stimulating a robust adaptive immune response involving both CD8+ T-cells, CD4+ T-cells, and B-cells.

Infants under 2 years old mount a poor immune response to T-independent antigens like bacterial polysaccharides. By conjugating the polysaccharide to a protein carrier, the B-cell that binds the polysaccharide can internalize the entire complex and present peptides from the protein carrier on its MHC class II molecules. This allows for recognition by carrier-specific helper T-cells, which then provide co-stimulation to the B-cell. This T-cell help is crucial for inducing immunoglobulin class switching (to IgG), affinity maturation, and the formation of long-lived memory B-cells.

The oral poliovirus vaccine (OPV) contains a live attenuated virus that replicates in the gastrointestinal tract, the natural site of poliovirus infection. This local replication effectively stimulates the mucosal-associated lymphoid tissue (MALT) to produce secretory IgA, which provides mucosal immunity and helps prevent initial infection and shedding of the virus. The inactivated polio vaccine (IPV) is injected and primarily induces a systemic IgG response, which prevents viremia and paralytic disease but is less effective at inducing mucosal immunity.

Adjuvants like aluminum salts are added to subunit and inactivated vaccines to enhance their immunogenicity. They function by creating a depot effect, slowly releasing the antigen over time, and, more importantly, by stimulating the innate immune system. They activate pattern recognition receptors, leading to local inflammation, recruitment of antigen-presenting cells (APCs), and upregulation of co-stimulatory molecules, which results in a more robust and durable adaptive immune response.

Live viral vaccines, like MMR, lead to the infection of host cells. Viral proteins are synthesized within these cells and processed through the endogenous pathway, leading to the presentation of viral peptides on MHC class I molecules. This presentation activates virus-specific CD8+ T-cells, which differentiate into cytotoxic T-lymphocytes (CTLs). CTLs are essential for identifying and killing virally infected host cells, thereby clearing the infection and contributing to long-term immunity.

Rabies immune globulin (RIG) is a preparation of concentrated, pre-formed anti-rabies antibodies. Its purpose is to provide immediate, passive immunity by binding to and neutralizing the rabies virus before it can enter the central nervous system. This temporary protection bridges the gap until the patient's own immune system can generate a protective active immune response, stimulated by the concurrently administered rabies vaccine.